Radiation boost may supercharge immunotherapy in breast cancer

NCT ID NCT04454528

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the tumor shrinks more than expected. Researchers will also check blood and tissue samples for signs of a stronger immune attack on the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (immunotherapy) and hypofractionated radiotherapy (radiation boost)
What this could lead to
If successful, this approach could shrink breast tumors before surgery and possibly improve long-term outcomes by harnessing the immune system.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply broadly. The combination may cause side effects or not improve response enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.